Table 3e. Dosing Regimens for the Drugs Recommended for the Treatment of MIS-C
Last Updated: July 21, 2023
For infants, children, and adolescents unless otherwise specified.
The doses listed are for FDA-approved indications for other diseases or from reported experiences or clinical trials.
|Adverse Events||Monitoring Parameters|
IVIG 2 g/kg IBW (up to a maximum total dose of 100 g) IV
In the event of cardiac dysfunction or fluid overload, consider administering IVIG in divided doses (1 g/kg IBW per dose IV every 24 hours for 2 doses).
Methylprednisolone 1–2 mg/kg IV every 12 hours
If the patient does not respond to 1–2 mg/kg IV every 12 hours, increase the dose to 10–30 mg/kg/day (up to maximum of 1,000 mg/day) IV for 1–3 days.
|Anakinra||Anakinra 5–10 mg/kg/day IV (preferred) or SUBQ in 1 to 4 divided doses|
|Infliximab||Infliximab 5–10 mg/kg IV for 1 dose|
|Aspirin||Aspirin 3–5 mg/kg (up to maximum of 81 mg) PO once daily|
Aged >2 Months to <18 Years
Key: AE = adverse effect; BMP = blood mineral panel; CBC = complete blood count; FDA = Food and Drug Administration; IBW = ideal body weight; IV = intravenous; IVIG = intravenous immunoglobulin; LFT = liver function test; MIS-C = multisystem inflammatory syndrome in children; PO = oral; SCr = serum creatinine; SUBQ = subcutaneous